Flip-flop pharmacokinetics--delivering a reversal of disposition: challenges and opportunities during drug development
about
A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate.Antileishmanial activity of a series of N²,N⁴-disubstituted quinazoline-2,4-diaminesA prospective population pharmacokinetic analysis of sapropterin dihydrochloride in infants and young children with phenylketonuria.Oral pharmacokinetics of the acidic drugs, diclofenac and sulfamonomethoxine in male Shiba goatsFew Drugs Display Flip-Flop Pharmacokinetics and These Are Primarily Associated with Classes 3 and 4 of the BDDCSPharmacokinetics of a peroral single dose of two long-acting formulations and an aqueous formulation of doxycycline hyclate in horsesPrediction of nanoparticle prodrug metabolism by pharmacokinetic modeling of biliary excretion.Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides.Evaluation of pharmacokinetic model designs for subcutaneous infusion of insulin aspart.Ulinastatin - a newer potential therapeutic option for multiple organ dysfunction syndrome.Drug-development concepts as guides for optimizing clinical trials of supplemental zinc for populations at risk of deficiency or diarrhea.Population-Based Pharmacokinetic and Exposure-Efficacy Analyses of Peginterferon Beta-1a in Patients With Relapsing Multiple Sclerosis.Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With SchizophreniaPharmacokinetics of Immediate and Sustained Release Cephalexin Administered by Different Routes to Llamas (Lama glama)Optimisation of microstructured biodegradable finasteride formulation for depot parenteral application.Is received dose from ingested soil independent of soil PAH concentrations?-Animal model results.Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous (ZTI-01) and Oral Fosfomycin in Healthy Volunteers.Amphotericin B concentrations in healthy mallard ducks (Anas platyrhynchos) following a single intratracheal dose of liposomal amphotericin B using an atomizer.Mechanistic in vitro studies confirm that inhibition of the renal apical efflux transporter multidrug and toxin extrusion (MATE) 1, and not altered absorption, underlies the increased metformin exposure observed in clinical interactions with cimetidCoupled solutions of one- and two-compartment pharmacokinetic models with first-order absorption.Disposition of [(14)C]hydroquinone in Harlan Sprague-Dawley rats and B6C3F1/N mice: species and route comparison.Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis.Kozeny-Carman permeability relationship with disintegration process predicted from early dissolution profiles of immediate release tablets.Simultaneous Determination of Three Furanocoumarins by UPLC/MS/MS: Application to Pharmacokinetic Study of Angelica dahurica Radix after Oral Administration to Normal and Experimental Colitis-Induced Rats.Monolithic LC method applied to fesoterodine fumarate low dose extended-release tablets: Dissolution and release kinetics.Population Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling of Depot Testosterone Cypionate in Healthy Male Subjects.Population pharmacogenetic pharmacokinetic modeling for flip-flop phenomenon of enteric-coated mycophenolate sodium in kidney transplant recipients.Pharmacokinetics and interspecies scaling of a novel, orally-bioavailable anti-cancer drug, SHetA2.Serum Triamcinolone Levels following Cervical Interlaminar Epidural Injection.Enhanced oral absorption of pemetrexed by ion-pairing complex formation with deoxycholic acid derivative and multiple nanoemulsion formulations: preparation, characterization, and in vivo oral bioavailability and anticancer effect.Population Pharmacokinetics of the Antimalarial Amodiaquine: A Pooled Analysis to Optimize DosingPopulation pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide
P2860
Q34414539-D2224CF2-F32E-47BB-AF32-B19F5FFDE3A1Q34435696-5D9A8686-8C04-468A-96F1-76C0337E9329Q35012215-253E812E-BFD9-4067-8B82-3858B6264A6FQ35147092-B6EB0CD9-C0DB-4811-A9CA-86912B7A1EE2Q35952140-F3C76CC9-CD65-416E-B98D-49CB4B31B7A1Q36716284-DD4C1802-A4CB-4A02-AD26-223E78BBD16FQ37210032-E339F7FB-1204-4432-A5F9-3A3C80D09742Q38110433-65170CF3-2B1B-4B5C-A176-707231861506Q38613015-9AB1926C-411C-4FD9-A1D1-14286281587AQ38632598-7768DE0B-02A5-46D3-AF83-F88030DAD45BQ38731793-D7730A18-8428-49AD-B76E-A4D968140DAFQ38844529-C07A5770-BE4D-4FB7-A383-793BF03F967FQ38871120-A8943FD7-22A0-4948-88F6-177A2C53B9B1Q39372487-A42307CD-70F5-486A-A6DA-7C7768830B42Q39990996-EC60569A-8122-4669-B589-E869E4FB09E4Q40056975-4A278DE6-6F65-4C48-8CB3-9ADF51F48C35Q40166194-06C8CEA2-8D71-43FB-8D1A-F2A88F0E5BD4Q41989595-82A39D6C-378A-437B-9C61-A2372DC811A4Q42099584-6E643B29-2A73-4C27-A227-2D689FB15091Q42267420-FAD07E31-C589-45B8-9680-C28B44F599BAQ46255908-3EFD0BD2-3383-4A58-9FB8-3455C4054913Q47628307-C81127F3-347B-4B8F-ACE5-FD96183E0394Q47937327-C1B2C4F4-A563-4F80-81F7-93F0E11B85DEQ47955618-9422F948-5C78-4BE8-B0E1-FD678AC498D9Q48504572-9B267D44-5D73-428E-987A-D0B4544D1AAEQ50045237-A6DE5F03-5ABE-4D6D-9A97-8B5DFC33B58BQ51048064-654FB126-680A-4963-A50B-26DC2443A9B9Q52381624-1B225C96-2965-4903-A165-ECC3F6DB7CD0Q55135183-1EDA2AA5-01C3-4B78-AAD7-B2FDD92A4D47Q55248249-1B52154B-253D-4E38-91C1-9176CC461667Q56358106-9A089F89-C41A-431F-B399-C68A7D4CF3ADQ58709296-E7445979-9C78-4541-8375-A88B4586D572
P2860
Flip-flop pharmacokinetics--delivering a reversal of disposition: challenges and opportunities during drug development
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Flip-flop pharmacokinetics--de ...... nities during drug development
@ast
Flip-flop pharmacokinetics--de ...... nities during drug development
@en
type
label
Flip-flop pharmacokinetics--de ...... nities during drug development
@ast
Flip-flop pharmacokinetics--de ...... nities during drug development
@en
prefLabel
Flip-flop pharmacokinetics--de ...... nities during drug development
@ast
Flip-flop pharmacokinetics--de ...... nities during drug development
@en
P2860
P50
P356
P1433
P1476
Flip-flop pharmacokinetics--de ...... nities during drug development
@en
P2093
Connie M Remsberg
Neal M Davies
P2860
P304
P356
10.4155/TDE.11.19
P577
2011-05-01T00:00:00Z